Scope Fluidics S.A. (GPW: SCP) – a biotechnology company listed in the sWIG80 index, operating under the Venture Studio model, had the honor of hosting U.S. Ambassador to the United States of America, Mark Brzezinski, at its headquarters. The U.S. Ambassador met with the Scope Fluidics team and familiarized himself with the process of developing the company’s groundbreaking new technologies.
Mark Brzezinski, U.S. Ambassador, remarked:
“I am delighted to have the opportunity today to witness up close how medical diagnostic technologies are being developed at Scope Fluidics. Poland is creating a high-tech ecosystem, and I see great potential for collaboration between Poland and the United States in this field. I eagerly anticipate further instances of fruitful exchange between American and Polish businesses, especially in the crucial area of healthcare, which holds such importance for our societies.”
Piotr Garstecki, Co-founder, significant shareholder, and CEO of Scope Fluidics, stated:
“It is an immense pleasure and honor for us to host Ambassador Brzezinski at Scope Fluidics. Collaboration with American companies is of great significance to us – the American healthcare, technology, and innovation markets play a key global role. We are pleased that the PCR|ONE technology has found capable hands in the American company Bio-Rad and that our collaboration with American entities is growing stronger.”
As part of the visit, the U.S. Ambassador had the opportunity to meet with members of the Scope Fluidics team and gain insight into the development process of the company’s technologies. The visit program also included a presentation of the BacterOMIC system.